By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Ophthotech Corporation 

One Penn Plaza, Suite 1924

New York  New York  10119  U.S.A.
Phone: 212-845-8200 Fax: 212-845-8250


Ophthotech is a biopharmaceutical company specializing in the development of novel therapeutics to treat back of the eye diseases, with a focus on developing innovative therapies for age-related macular degeneration (AMD). Ophthotech's most advanced product candidate, Fovista® anti-PDGF therapy, is in Phase 3 clinical trials for use in combination with anti-VEGF therapy that represents the current standard of care for the treatment of wet AMD. Ophthotech's second product candidate, Zimura®, an inhibitor of complement factor C5, is being developed for the treatment of geographic atrophy, a form of dry AMD, and in combination with anti-VEGF therapy in wet AMD patients to potentially reduce the treatment burden. For more information, please visit


One Penn Plaza
Suite 1924
New York, NY 10119
Phone (212) 845-8200
Fax (212) 845-8250

One University Square Drive
Suite 280
Princeton, NJ 08540
Phone (609) 945-6050
Fax (609) 452-7435

Key Statistics

Email: n/a
Ownership: Public

Web Site: Ophthotech Corporation
Symbol: OPHT

Company News
Ophthotech Corporation (OPHT) Completes Patient Recruitment In Phase 3 Trial Of Fovista Anti-PDGF Therapy In Combination With Eylea Or Avastin In Wet Age-Related Macular Degeneration 6/20/2016 11:50:22 AM
Ophthotech Corporation (OPHT) To Present At The Goldman, Sachs & Co. 37th Annual Global Healthcare Conference 5/31/2016 10:41:25 AM
Ophthotech Corporation (OPHT) Reports First Quarter 2016 Financial And Operating Results 5/4/2016 10:49:07 AM
Carmen A. Puliafito, MD, MBA, Former Dean Of Keck School Of Medicine Of The University of Southern California, Joins Ophthotech Corporation (OPHT) As Chief Of Strategic Development 4/28/2016 11:35:53 AM
Ophthotech Corporation (OPHT) To Report First Quarter 2016 Financial Results And Host Conference Call On Wednesday, May 4, 2016 4/26/2016 12:02:52 PM
Ophthotech Corporation (OPHT) To Present At Barclays Global Healthcare Conference 2016 3/8/2016 11:25:15 AM
Ophthotech Corporation (OPHT) Reports Fourth Quarter And Full Year 2015 Financial And Operating Results 2/24/2016 11:31:54 AM
Ophthotech Corporation (OPHT) To Present At RBC Capital Markets Healthcare Conference 2/18/2016 10:50:02 AM
Ophthotech Corporation (OPHT) To Present At The LEERINK Partners 5th Annual Global Healthcare Conference 2/3/2016 11:58:53 AM
Ophthotech Corporation (OPHT) Announces First Patient Dosed In Zimura Phase 2/3 Study To Evaluate Treatment In Patients With Geographic Atrophy, An Advanced Form Of Dry Age-Related Macular Degeneration 1/27/2016 10:01:48 AM